Open Access<p>Induction Of XLF And 53BP1 Expression Is Associated With Temozolomide Resistance In Glioblastoma Cells</p>
Author(s) -
Tongxia Zhang,
Jie Chai,
Chi L
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s221025
Subject(s) - temozolomide , cancer research , western blot , microbiology and biotechnology , dna repair , cell growth , apoptosis , cell culture , chemistry , downregulation and upregulation , chromatin , biology , glioma , dna , genetics , gene , biochemistry
Glioblastoma (GBM) is the most commonly diagnosed primary brain tumor in adults. The 14.6 months median survival period of GBM patients is still palliative due to resistance to the first-line chemotherapeutic agent temozolomide (TMZ).